Aurinia Pharmaceuticals Inc (AUPH) is a publicly traded Healthcare sector company. As of July 6, 2026, AUPH trades at $15.84 with a market cap of $2.01B and a P/E ratio of 6.91. AUPH moved +1.70% today. Year to date, AUPH is -1.33%; over the trailing twelve months it is +108.41%. Its 52-week range spans $6.55 to $19.25. Analyst consensus is buy with an average price target of $15.67. Rallies surfaces AUPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aurinia Launches PRESERVE Trial Testing LUPKYNIS with Three Biologics: Aurinia initiated PRESERVE, a multi-arm clinical study evaluating LUPKYNIS combined with belimumab, obinutuzumab or anifrolumab in patients with active lupus nephritis. The trial will assess safety and efficacy across three combination regimens to determine potential improvements in renal response and immunologic outcomes.
| Metric | Value |
|---|---|
| Price | $15.84 |
| Market Cap | $2.01B |
| P/E Ratio | 6.91 |
| EPS | $2.26 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.25 |
| 52-Week Low | $6.55 |
| Volume | 253.83K |
| Avg Volume | 0 |
| Revenue (TTM) | $298.30M |
| Net Income | $298.21M |
| Gross Margin | 89.74% |
3 analysts cover AUPH: 0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.67.